View Older Stories View More Recent Stories

Jun 29, 2016 08:00AM BioTime Presents Online Resource for Applying Artificial Intelligence to Stem Cell Biology at Mensa 2016 Annual Gathering
Jun 21, 2016 11:55AM BioTime, Inc. Announces Closing of Public Offering of Common Stock
Jun 16, 2016 09:56AM BioTime (BTX) Prices 7.3M Stock Offering at $2.39/Share
Jun 16, 2016 09:41AM BioTime, Inc. Announces Pricing of Public Offering of Common Stock
Jun 15, 2016 04:09PM BioTime (BTX) Announces Common Stock Offering
Jun 15, 2016 04:08PM BioTime, Inc. Announces Proposed Public Offering of Common Stock
Jun 13, 2016 07:12AM BioTime (BTX), Cell Cure Receive DSMB Approval to Move Forward with OpRegen Phase 1/2a Enrollment
Jun 13, 2016 07:00AM BioTime’s Subsidiary Cell Cure Neurosciences Receives DSMB Approval to Start Second Patient Cohort in Clinical Trial for Dry-AMD
Jun 10, 2016 09:35AM BioTime (BTX) Unit Receives $2.2M Grant for Development of OpRegen in Dry-AMD
Jun 10, 2016 09:27AM BioTime Announces $2.2 Million Grant for Further Development of Dry-AMD Program
Jun 9, 2016 07:00AM BioTime to Present at the Jefferies 2016 Global Healthcare Conference
May 20, 2016 05:08PM BioTime to Present at Two Upcoming Investor Conferences
May 10, 2016 05:01PM BioTime, Inc. Reports First Quarter Results and Recent Corporate Accomplishments
Apr 26, 2016 08:00AM BioTime Co-CEO Dr. Michael West Presents at Biomedical Innovation for Healthy Longevity, International Conference
Apr 5, 2016 08:30AM BioTime Co-CEO Dr. Michael West to Present at Stem Cells in Drug Discovery 2016 in Cambridge, UK
Mar 21, 2016 08:30AM BioTime, Inc. to Host Conference Call to Update Investors on Recent Accomplishments and Corporate Objectives for 2016
Feb 24, 2016 09:03AM BioTime (BTX) Unit Completes End-of-Phase II FDA Meeting for AST-VAC1 in AML
Feb 24, 2016 09:00AM BioTime Subsidiary Asterias Biotherapeutics Reports the Successful End-of-Phase II FDA Meeting for Immunotherapy in Acute Myeloid Leukemia
Feb 16, 2016 06:53PM BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents
Feb 1, 2016 01:17PM BioTime, Inc. to Present at Three Investor Conferences in February
Jan 21, 2016 07:03AM Asterias Biotherapeutics (AST) Completes Transer of AST-VAC2 Manufacturing to Cancer Research UK
Jan 21, 2016 07:00AM Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial
Jan 12, 2016 05:27PM Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring October 1, 2018
Dec 31, 2015 09:00AM BioTime Completes Distribution of Approximately 4.75 Million Shares of OncoCyte Corporation Common Stock
Dec 11, 2015 07:27PM BioTime Co-Chief Executive Officer Michael D. West, PhD to Deliver Keynote Speech at the 2015 World Stem Cell Summit
Dec 11, 2015 08:50AM BioTime, Inc. Announces Record Date, Distribution Ratio, and Distribution Date for Distribution of Shares of Subsidiary OncoCyte Corporation
Dec 4, 2015 06:00AM BioTime, Inc. to Present at Oppenheimer Annual Healthcare Conference
Nov 18, 2015 08:00AM BioTime, Inc. Announces the Appointment of Life Sciences Industry Veteran Russell Skibsted as Chief Financial Officer
Nov 9, 2015 08:00AM BioTime, Inc. Reports Third Quarter 2015 Results and Recent Corporate Accomplishments
Nov 6, 2015 08:00AM BioTime, Inc. and Hepregen Corporation Form Ascendance Biotechnology, Inc. to Address the In Vitro Cell Biology Market
Oct 19, 2015 07:00AM Adi Mohanty Joins Michael D. West, PhD, as Co-CEO of BioTime, Inc.
Oct 7, 2015 04:15PM BioTime’s Subsidiary OncoCyte Corporation Files Form 10 Registration Statement for Planned Distribution
Oct 2, 2015 09:02AM BioTime, Inc. Agrees to Sell $5.1 Million of Equity
Oct 1, 2015 03:17PM BioTime Announces the Closing of a $20 Million Direct Registered Offering; Demand Exceeds NIS 80 Million Offered
Sep 30, 2015 04:00AM Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements
Sep 29, 2015 09:00AM Mount Sinai and LifeMap Solutions Announce Initial Results for Asthma Health App and New Features to Enhance Clinical Impact
Sep 28, 2015 08:00AM BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Receives FDA Fast-Track Designation for OpRegen® for the Treatment of the Dry Form of Age-Related Macular Degeneration
Sep 25, 2015 05:08PM BioTime, Inc. Agrees to Sell Up to $20.7 Million of Common Shares
Sep 14, 2015 07:00AM BioTime, Inc. Agrees to Sell $8.58 Million of Common Shares
Sep 4, 2015 09:06AM BioTime Announces Dual Listing on the Tel Aviv Stock Exchange
Sep 1, 2015 08:30AM BioTime Chief Executive Officer Dr. Michael D. West to be Keynote Speaker at Stem Cells & Regenerative Medicine Congress 2015
Aug 31, 2015 01:06PM BioTime Subsidiary Asterias Therapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury
Aug 28, 2015 08:30AM BioTime Management to Present at Rodman & Renshaw 17th Annual Global Investment Conference
Aug 18, 2015 07:30AM The Wistar Institute and BioTime Subsidiary OncoCyte Corporation Expand Agreement to Develop Molecular Diagnostic Test for the Detection of Lung Cancer
Aug 10, 2015 05:07PM BioTime, Inc. Reports Second Quarter 2015 Results and Recent Developments
Aug 10, 2015 08:30AM BioTime Announces the Issuance of 27 New Patents Protecting Stem Cell-Based Product Development
Jul 15, 2015 08:30AM OncoCyte Announces Appointment of Andy Arno to Board of Directors
Jun 16, 2015 08:30AM William Annett Named Chief Executive Officer of OncoCyte Corporation
May 20, 2015 08:00AM BioTime to Present at the Jefferies 2015 Global Healthcare Conference
May 19, 2015 08:00AM OncoCyte’s Collaborators at The Wistar Institute Present Positive Clinical Interim Results of Blood-Based Diagnostic Test for Non-Invasive Detection of Lung Cancer
View More Recent Stories View Older Stories